Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTWCGQT)

• DTT Name: Serine/threonine-protein kinase B-raf (BRAF) DTT Info
• Gene Name: BRAF

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[1]
LGX818	DMNQXV8	Melanoma	2C30	Approved	[2]
Vemurafenib	DM62UG5	Melanoma	2C30	Approved	[3]

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PLX8394	DMRTD7I	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
BGB-283	DMVYTG7	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
CEP-32496	DMAO04B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
ABM-1310	DMS1HR3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
ARQ 736	DMP9ZT1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
ASN003	DMJCX6D	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
BMS-908662	DM3K8VM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
PF-07284890	DMK7XYH	Melanoma	2C30	Phase 1	[11]
PF-07799933	DMHGA0S	Aggressive cancer	2A00-2F9Z	Phase 1	[12]
RO-5212054	DML4C3Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG-7256	DM0LXBW	Melanoma	2C30	Discontinued in Phase 1	[14]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AR-00341677	DMK2XB7	Solid tumour/cancer	2A00-2F9Z	Investigative	[15]
AZ-628	DMEWQHP	Solid tumour/cancer	2A00-2F9Z	Investigative	[16]

References

• [1] Clinical pipeline report, company report or official report of GlaxoSmithKline (2011).
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.
• [5] BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
• [6] Clinical pipeline report, company report or official report of Ambit Biosciences.
• [7] Clinical pipeline report, company report or official report of ABM Therapeutics.
• [8] National Cancer Institute Drug Dictionary (drug id 688029).
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of Exelixis (2011).
• [11] Clinical pipeline report, company report or official report of Pfzer
• [12] ClinicalTrials.gov (NCT05355701) A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS. U.S.National Institutes of Health.
• [13] National Cancer Institute Drug Dictionary (drug id 680347).
• [14] First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Target Oncol. 2016 Apr;11(2):149-56.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5681).
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8475).